Stay updated on Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page.

Latest updates to the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing the previous Revision: v3.4.1. This is a minor site version update that does not change study details.SummaryDifference0.1%

- Check12 days agoChange DetectedThe page now displays 'Revision: v3.4.1', replacing the previous 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedAdds a glossary toggle and updates footer metadata to include 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0,' while removing older capitalization and wording.SummaryDifference0.2%

- Check34 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4. This appears to be a routine backend version change with no impact on the study details or user-facing content.SummaryDifference0.1%

- Check55 days agoChange DetectedA consolidated 'Locations' section was added listing California, Indiana, Kentucky, Nebraska, New Jersey, and Virginia, with the former separate state location entries removed; the revision tag was updated from v3.3.2 to v3.3.3.SummaryDifference0.7%

- Check83 days agoChange DetectedAdded `Revision: v3.3.2` and removed `Revision: v3.2.0`.SummaryDifference0.1%

Stay in the know with updates to Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page.